Massive study reveals best Second-Line diabetes meds for heart and kidney protection
NCT ID NCT05220917
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This study looks at health records from over 780,000 people with type 2 diabetes to compare four common second-line medications: SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas. The goal is to see which drug class is most effective at preventing heart attacks, strokes, heart failure, and kidney problems. Participants are adults with type 2 diabetes who are already taking metformin and have low to moderate heart risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR EVENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Exercise and a diabetes drug: a One-Two punch for blood vessels?
- Flu vaccine showdown: which shot protects seniors best?
- Could Weight-Loss surgery slash heart risks in diabetes?
- One infusion, two targets: a uric-acid-lowering drug takes aim at heart and kidney disease in youth-onset diabetes
- Could a Two-Drug combo stop repeat heart attacks?
- Can exercise slash heart and diabetes risks in latina breast cancer survivors?